GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Net Change in Cash

Median Technologies (XPAR:ALMDT) Net Change in Cash : €-1.97 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Median Technologies Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Median Technologies's Net Change in Cash for the six months ended in Dec. 2023 was €11.16 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.97 Mil.

Median Technologies Net Change in Cash Historical Data

The historical data trend for Median Technologies's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Technologies Net Change in Cash Chart

Median Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.12 8.70 22.69 -17.54 -1.97

Median Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 -10.77 -6.77 -13.13 11.16

Median Technologies Net Change in Cash Calculation

Median Technologies's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-20.236+-1.253+19.722+-0.203
=-1.97

Median Technologies's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-8.153+-0.739+20.046+0.004
=11.16

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Median Technologies Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Median Technologies's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Median Technologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Median Technologies (XPAR:ALMDT) » Definitions » Net Change in Cash
Comparable Companies
XPAR:ALBIO XPAR:ALCAR XPAR:AFME XPAR:ALNOV XPAR:ALMKT XPAR:ALTHE XPAR:ALTER XPAR:ALBLU XPAR:ALDMS XPAR:ALEMG ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
4ZG:Germany
Address
1800 Route Des Cretes, Les Deux Arcs B, Valbonne, FRA, 06560
Website
https://www.mediantechnologies.com
Median Technologies is engaged in providing medical imaging products and services for diagnosing and monitoring cancer patients in both routine clinical practice and clinical drug development. The firm intends to target the oncology clinical trials market and the cancer patient care market. It developed software-based tools that are integrated into a clinical application portfolio called Lesion Management Solutions. The company has two platforms, iSee for imaging services in clinical trials and iBiopsy for non-invasive diagnostic tests based on imaging for the treatment of patients suffering from cancer and other chronic diseases. Its geographical segments are France, the USA/Canada, the United Kingdom, China, and Other countries.

Median Technologies Headlines

No Headlines